
-
CRISPR Therapeutics NasdaqGM:CRSP CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Location: Baarerstrasse 14, Zug, 6300, Switzerland | Website: https://www.crisprtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.541B
Cash
1.855B
Avg Qtr Burn
-76.62M
Short % of Float
24.51%
Insider Ownership
1.75%
Institutional Own.
76.60%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Approved Quarterly sales | ||
CTX110 (CD19) Details CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer | Phase 2 Update | |
Phase 1/2 Update | ||
Phase 1/2 Update | ||
CTX211 (formerly VCTX211) Details Type 1 diabetes | Phase 1/2 Update | |
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma | Phase 1 Update | |
VCTX210 Details Type 1 diabetes | Phase 1 Update | |
CTX131 (CD70) Details Cancer, Solid tumor/s | Phase 1 Update | |
CTX112 Details Systemic lupus erythematosus | Phase 1 Update | |
CTX112 Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies | Phase 1 Update | |
CTX310 (ANGPTL3) Details Atherosclerotic cardiovascular disease | Phase 1 Update | |
CTX320 Lp(a) Details Atherosclerotic cardiovascular disease | Phase 1 Update | |
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer | Failed Discontinued |